U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06985615) titled 'A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement' on May 15.
Brief Summary: The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of HDM1002
Study Start Date: March 18
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Healthy Volunteers
Intervention:
DRUG: Single dose of HDM1002 on Day 1
Single dose of HDM1002 will be administered on Day 1
Recruitment Status: RECRUITING
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission f...